FdaApplication
NDA 217469
Identifiers
- fda_app_no: NDA217469
Properties
| Property | Value |
|---|---|
| applicant_name | HARROW EYE LLC |
| application_type | NDA |
| approval_date | 2023-05-30 |
Revenue by product
VEVYE
| Period | Revenue |
|---|---|
| Q2 2026 | $29.4M |
| Q1 2026 | $20.9M |
| Q4 2025 | $25.9M |
| Q3 2025 | $22.6M |
| Q2 2025 | $37.3M |
| Q1 2025 | $21.5M |
| Q4 2024 | $16.0M |
| Q3 2024 | $5.2M |
| Q2 2024 | $4.3M |
| Q1 2024 | $2.6M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VEVYE | CYCLOSPORINE | 0.1% | SOLUTION;OPHTHALMIC |
1 product